cas 2106-02-7|| where to buy 2-Chloro-4-fluoroaniline

Nom du produit:2-Chloro-4-fluoroaniline

IUPAC Name:2-chloro-4-fluoroaniline

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM118192-500g	in stock	ŉǤǤ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2106-02-7 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:2106-02-7; Formule moléculaire:C6H5ClFN; Point de fusion:-; Code SMILES:NC1=CC=C(F)C=C1Cl; Densité:

: Numéro de catalogue:CM118192; Poids moléculaire:145.56; Point d'ébullition:; N° Mdl:MFCD00042530; Stockage:

: Nitrogen Compounds; Nitrogen compounds can be classified as mineral or organic. Mineral compounds are essentially formed by the ammonium ion (NH4+), which is generated when ammonium salts are dissolved in water. Organic compounds, in contrast, are carbon and hydrogen compounds that contain a nitrogen atom. All organic nitrogen-containing compounds can be considered as derivatives of ammonia in which one or more hydrogen atoms are substituted by hydrocarbon radicals.

: Tinlorafenib; The Journal of Medicinal Chemistry releases an article titled "Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer". Mutations in the BRAF gene result in MAPK pathway activation that are most commonly found in human melanomas. The BRAF V600E mutation is among the most frequent types. Present BRAF inhibitors have significantly improved treatment outcomes for patients with BRAF V600-mutant cancers. However, their effectiveness is limited by disease progression in the brain as they don’t adequately penetrate the blood-brain barrier (BBB).
Pfizer’s Tinlorafenib (formerly PF 07284890) is a highly brain-penetrant inhibitor of BRAF V600-mutant tumors, and currently in a phase 1 clinical trial (NCT04543188).